stomach cancer

New cancer biosimilar could net major salesA new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.
FDA approves Cyramza in combination with paclitaxel for advanced gastric cancer after prior chemotherapyFDA has approved ramucirumab (Cyramza, Eli Lilly) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
FDA approves advanced stomach cancer drugFDA approved ramucirumab (Cyramza, Eli Lilly) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma.
Advanced stomach cancer drug approvedFDA approved ramucirumab (Cyramza, Eli Lilly) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma.